Andrew B Crouse1, Tiffany Grimes2, Peng Li3, Matthew Might1, Fernando Ovalle2, Anath Shalev2. 1. Hugh Kaul Precision Medicine Institute, University of Alabama at Birmingham, Birmingham, AL, United States. 2. Comprehensive Diabetes Center, Department of Medicine, Division of Endocrinology, Diabetes and Metabolism, University of Alabama at Birmingham, Birmingham, AL, United States. 3. School of Nursing, University of Alabama at Birmingham, Birmingham, AL, United States.
Abstract
Background: Coronavirus disease-2019 (COVID-19) is a growing pandemic with an increasing death toll that has been linked to various comorbidities as well as racial disparity. However, the specific characteristics of these at-risk populations are still not known and approaches to lower mortality are lacking. Methods: We conducted a retrospective electronic health record data analysis of 25,326 subjects tested for COVID-19 between 2/25/20 and 6/22/20 at the University of Alabama at Birmingham Hospital, a tertiary health care center in the racially diverse Southern U.S. The primary outcome was mortality in COVID-19-positive subjects and the association with subject characteristics and comorbidities was analyzed using simple and multiple linear logistic regression. Results: The odds ratio of contracting COVID-19 was disproportionately high in Blacks/African-Americans (OR 2.6; 95% CI 2.19-3.10; p<0.0001) and in subjects with obesity (OR 1.93; 95% CI 1.64-2.28; p<0.0001), hypertension (OR 2.46; 95% CI 2.07-2.93; p<0.0001), and diabetes (OR 2.11; 95% CI 1.78-2.48; p<0.0001). Diabetes was also associated with a dramatic increase in mortality (OR 3.62; 95% CI 2.11-6.2; p<0.0001) and emerged as an independent risk factor in this diverse population even after correcting for age, race, sex, obesity, and hypertension. Interestingly, we found that metformin treatment prior to diagnosis of COVID-19 was independently associated with a significant reduction in mortality in subjects with diabetes and COVID-19 (OR 0.33; 95% CI 0.13-0.84; p=0.0210). Conclusion: Thus, these results suggest that while diabetes is an independent risk factor for COVID-19-related mortality, this risk is dramatically reduced in subjects taking metformin prior to diagnosis of COVID-19, raising the possibility that metformin may provide a protective approach in this high risk population.
Background: Coronavirus disease-2019 (COVID-19) is a growing pandemic with an increasing death toll that has been linked to various comorbidities as well as racial disparity. However, the specific characteristics of these at-risk populations are still not known and approaches to lower mortality are lacking. Methods: We conducted a retrospective electronic health record data analysis of 25,326 subjects tested for COVID-19 between 2/25/20 and 6/22/20 at the University of Alabama at Birmingham Hospital, a tertiary health care center in the racially diverse Southern U.S. The primary outcome was mortality in COVID-19-positive subjects and the association with subject characteristics and comorbidities was analyzed using simple and multiple linear logistic regression. Results: The odds ratio of contracting COVID-19 was disproportionately high in Blacks/African-Americans (OR 2.6; 95% CI 2.19-3.10; p<0.0001) and in subjects with obesity (OR 1.93; 95% CI 1.64-2.28; p<0.0001), hypertension (OR 2.46; 95% CI 2.07-2.93; p<0.0001), and diabetes (OR 2.11; 95% CI 1.78-2.48; p<0.0001). Diabetes was also associated with a dramatic increase in mortality (OR 3.62; 95% CI 2.11-6.2; p<0.0001) and emerged as an independent risk factor in this diverse population even after correcting for age, race, sex, obesity, and hypertension. Interestingly, we found that metformin treatment prior to diagnosis of COVID-19 was independently associated with a significant reduction in mortality in subjects with diabetes and COVID-19 (OR 0.33; 95% CI 0.13-0.84; p=0.0210). Conclusion: Thus, these results suggest that while diabetes is an independent risk factor for COVID-19-related mortality, this risk is dramatically reduced in subjects taking metformin prior to diagnosis of COVID-19, raising the possibility that metformin may provide a protective approach in this high risk population.
Authors: Konstantin Tsoyi; Hwa Jin Jang; Irina Tsoy Nizamutdinova; Young Min Kim; Young Soo Lee; Hye Jung Kim; Han Geuk Seo; Jae Heun Lee; Ki Churl Chang Journal: Br J Pharmacol Date: 2011-04 Impact factor: 8.739
Authors: Christian Christiansen; Martin Johansen; Steffen Christensen; James M O'Brien; Else Tønnesen; Henrik Sørensen Journal: Crit Care Date: 2013-09-09 Impact factor: 9.097
Authors: Christine M Hunt; Jimmy T Efird; Thomas S Redding; Andrew D Thompson; Ashlyn M Press; Christina D Williams; Christopher J Hostler; Ayako Suzuki Journal: J Gen Intern Med Date: 2022-06-29 Impact factor: 6.473
Authors: Rachel Wong; Margaret Hall; Rohith Vaddavalli; Adit Anand; Neha Arora; Carolyn T Bramante; Victor Garcia; Steven Johnson; Mary Saltz; Jena S Tronieri; Yun Jae Yoo; John B Buse; Joel Saltz; Joshua Miller; Richard Moffitt Journal: Diabetes Care Date: 2022-02-24 Impact factor: 17.152
Authors: Michelle A Lally; Philip Tsoukas; Christopher W Halladay; Emily O'Neill; Stefan Gravenstein; James L Rudolph Journal: J Am Med Dir Assoc Date: 2020-10-26 Impact factor: 4.669
Authors: Shirley Sze; Daniel Pan; Clareece R Nevill; Laura J Gray; Christopher A Martin; Joshua Nazareth; Jatinder S Minhas; Pip Divall; Kamlesh Khunti; Keith R Abrams; Laura B Nellums; Manish Pareek Journal: EClinicalMedicine Date: 2020-11-12
Authors: Hayder M Al-Kuraishy; Ali I Al-Gareeb; M Alblihed; Susana G Guerreiro; Natália Cruz-Martins; Gaber El-Saber Batiha Journal: Front Cardiovasc Med Date: 2021-05-20